|
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC). |
|
|
Honoraria - Alchemia; Amgen; Bayer; Merck; Roche; Sirtex Medical |
Research Funding - Pfizer (Inst); Roche (Inst) |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Sirtex Medical |
Speakers' Bureau - Sirtex Medical |
Research Funding - Sirtex Medical (Inst) |
Travel, Accommodations, Expenses - Sirtex Medical |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Sirtex Medical |
Speakers' Bureau - Sirtex Medical |
Travel, Accommodations, Expenses - Sirtex Medical |
|
|
Consulting or Advisory Role - Lilly (Inst); Merck Serono (Inst); Sirtex Medical (Inst); Te Arai BioFarma (Inst) |
Travel, Accommodations, Expenses - Lilly; Sirtex Medical; Te Arai BioFarma |
|
|
No Relationships to Disclose |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Sirtex Medical |
Travel, Accommodations, Expenses - Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Boehringer Ingelheim; Lilly; Merck; Roche Pharma AG; Sanofi; Sirtex Medical |
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Lilly; Merck; Roche Pharma AG; Sanofi; Sirtex Medical |
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Sirtex Medical (Inst) |
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; Lilly; Merck; Roche Pharma AG; Sanofi; Sirtex Medical |